Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized 26-Week Placebo-Controlled Efficacy and Safety Study With a 26-Week Long-Term Safety Extension of High- and Medium-Dose Inhaled Mometasone Furoate/Formoterol Fixed-Dose Combination Formulation Compared With Formoterol and High-Dose Inhaled Mometasone Furoate Monotherapy in Subjects With Moderate to Severe COPD.

X
Trial Profile

A Randomized 26-Week Placebo-Controlled Efficacy and Safety Study With a 26-Week Long-Term Safety Extension of High- and Medium-Dose Inhaled Mometasone Furoate/Formoterol Fixed-Dose Combination Formulation Compared With Formoterol and High-Dose Inhaled Mometasone Furoate Monotherapy in Subjects With Moderate to Severe COPD.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 17 Feb 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mometasone/formoterol (Primary) ; Formoterol; Mometasone
  • Indications Chronic obstructive pulmonary disease
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 06 Mar 2012 Results at 26 weeks presented at the 68th Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
    • 27 Oct 2011 HRQOL results for this trial and the identical phase III trial (NCT00383721; clinical trial profile 28826) were presented together at the 77th Annual Meeting of the American College of Chest Physicians: Chest 2011.
    • 24 Oct 2011 Results from this trial have been presented at the 77th Annual Meeting of the American College of Physicians, according to a Merck media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top